Safety of Bedside Placement of Tunneled Hemodialysis Catheters In The Intensive Care Unit: Translating From The Covid-19 Experience – Retrospective Single-Center Case Series

Mohammad Ahsan Sohail (sohailm@ccf.org)  
Cleveland Clinic Foundation: Cleveland Clinic  https://orcid.org/0000-0001-8701-3207

Tarik Hanane  
Cleveland Clinic Foundation: Cleveland Clinic

James Lane  
Cleveland Clinic Foundation: Cleveland Clinic

Tushar Vachharajani  
Cleveland Clinic Foundation: Cleveland Clinic

Research

Keywords: COVID-19, Tunneled Dialysis Catheter, Intensive Care Unit, Anatomic Landmarks, Bedside Procedure, Ultrasound

DOI: https://doi.org/10.21203/rs.3.rs-762537/v1

License: © This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

Background: Critically-ill patients with coronavirus disease-2019 (COVID-19) and kidney dysfunction often require tunneled hemodialysis catheter (TDC) placement for kidney replacement therapy (KRT), typically under fluoroscopic guidance to minimize catheter-related complications. This entails transportation of patients outside the intensive care unit (ICU) to a fluoroscopy suite, which may potentially expose many healthcare providers to COVID-19. One potential strategy to mitigate the risk of viral transmission is to insert TDCs at the bedside, using ultrasound (US) and anatomic landmarks only, without fluoroscopic guidance.

Methods: We reviewed all COVID-19 patients in the ICU who underwent right internal jugular (RIJ) TDC insertion at the bedside between April and December 2020. Outcomes included procedural complications such as bleeding, venous air embolism, arrhythmias, pneumothorax and catheter tip malposition. TDC insertion was considered successful if the catheter was able to achieve blood flow sufficient to perform a single hemodialysis treatment.

Results: We report a retrospective single-center case series of 25 patients with COVID-19 who had RIJ TDCs placed at the bedside, 10 of whom underwent simultaneous insertion of small-bore RIJ tunneled central venous catheters (T-CVC). Continuous veno-venous hemodialysis was the KRT modality employed in all patients. A median catheter blood flow rate of 200 ml/min (IQR:200-200) was achieved in all patients without any deviation from the dialysis prescription. No catheter-related complications were observed and none of the catheter tips were mal-positioned.

Conclusions: Bedside RIJ TDC placement in COVID-19 patients, using US and anatomic landmarks without fluoroscopic guidance, may potentially reduce the risk of COVID-19 transmission amongst healthcare workers without compromising patient safety or catheter function.

Background

The global coronavirus disease-2019 (COVID-19) pandemic, caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has posed unique challenges for infection prevention and control within healthcare facilities [1]. Critical care providers, in particular, are currently faced with multiple challenges pertaining to the clinical management of patients with COVID-19 such as preventing infection transmission, maintaining a safe work environment for the intensive care unit (ICU) staff, as well as minimizing the stress on work force capacity and infrastructure [2].

Kidney involvement in critically-ill patients with COVID-19 is commonly observed [3], often requiring placement of a tunneled hemodialysis catheter (TDC) to initiate kidney replacement therapy [4,5]. The standard clinical practice for TDC placement involves using ultrasound and fluoroscopic guidance, ensuring minimal immediate procedural complications with appropriate catheter-tip positioning in the mid-right atrium [6]. This entails transporting the patient from the ICU to a fluoroscopy suite and potentially exposing numerous health care professionals and ancillary staff to SARS-CoV-2 infected
patients [2]. One potential strategy to limit the exposure of multiple hospital staff members to COVID-19 involves bedside placement of TDCs in the ICU under continuous cardiac monitoring, using anatomic landmarks and ultrasound only, without fluoroscopic guidance [7].

However, it should also be acknowledged that the use of fluoroscopy reduces the risk of catheter placement related complications [6], which contribute significantly to patients’ morbidity and mortality as well as increased economic burden to the society [8]. Consequently, bedside TDC placement using anatomic landmarks should only be performed in well selected patients to ensure that we do not compromise patient safety or quality of care in an attempt to reduce COVID-19 transmission amongst health care personnel.

In this study, our objective was to evaluate the safety and effectiveness of bedside TDC placement without fluoroscopic guidance in carefully selected patients with COVID-19. We hypothesized that bedside TDC placement in select patients by experienced providers in the ICU utilizing ultrasound guidance and anatomic landmarks, without having to transport SARS-CoV-2 infected patients to the fluoroscopy suite, can be successfully accomplished without compromising patient safety or catheter function.

**Patients And Methods**

**STUDY DESIGN, LOCATION AND OUTCOMES**

We report a retrospective single-center case series conducted at the Cleveland Clinic in Cleveland, Ohio. The study protocol was reviewed and approved by the institutional review board at the Cleveland Clinic and the protocol was exempted from the requirement for informed consent from patients since only de-identified data collected during hospital visits were included in the study.

The primary objectives of this study were to evaluate the safety and efficacy of bedside TDC placement in patients with COVID-19 in the ICU without fluoroscopic guidance, specifically investigating the incidence of immediate procedure related complications and catheter dysfunction following TDC insertion. Outcomes considered to evaluate the safety of bedside TDC insertion included incidence of procedural complications such as bleeding, arterial puncture, venous air embolism, arrhythmias, pneumothorax, hemothorax and catheter tip malposition [9,10]. The optimal position for the tip of the TDCs was considered to be either within the mid-right atrium or at the junction of the superior vena cava (SVC) and the right atrium as confirmed with a post-procedure chest radiograph [11].

Outcomes considered to assess the efficacy of bedside TDC placement included dialysis prescription parameters such as blood flow rate and ultrafiltration rate. TDC insertion was considered to be successful when the catheter was able to sustain the prescribed blood flow to perform either a single intermittent or 24 hours of continuous hemodialysis treatment.
STUDY POPULATION AND SELECTION CRITERIA FOR TDC INSERTION

We conducted a retrospective chart review of all adult patients with COVID-19 in the ICU who underwent right internal jugular (IJ) TDC placement at the bedside utilizing anatomic landmarks and ultrasound guidance between April 1st 2020 and December 31st 2020 at the Cleveland Clinic. The diagnosis of COVID-19 infection was confirmed with a positive nucleic acid amplification test for SARS-CoV-2. Pre-procedural inclusion and exclusion criteria for patients prior to TDC insertion are delineated in Table 1.

PROTOCOL FOR BEDSIDE TUNNELED DIALYSIS CATHETER PLACEMENT

Consultations for tunneled dialysis access from the medical ICU were reviewed carefully by the ICU procedural team to determine eligibility for bedside TDC insertion based on the patient selection criteria mentioned in Table 1. After identification of an appropriate candidate, the medical ICU procedure room was notified, and a cart with the necessary equipment and multiple lengths of TDCs was prepared.

The procedure was performed at the bedside using personal protective equipment (PPE) for COVID-19 as per hospital policy and standard aseptic practices [12,13] by a trained attending proceduralist, experienced with tunneled dialysis catheter placements under fluoroscopy, assisted by one procedure nurse. Sedation for the procedure was managed by the attending physician and the patient’s bedside ICU nurse. TDC placement into the right IJ vein was considered to be a safe initial protocol for bedside insertion of TDCs under continuous cardiac monitoring without fluoroscopic guidance.

The protocol for right IJ TDC insertion using anatomic landmarks as previously published [14] can be briefly described as using the manubrial-sternal angle as the topographical landmark that corresponds to the carina, with the insertion depth estimated by measuring the distance between the skin venipuncture site 1–2 cm above the clavicle and a point 5 cm below the manubrial-sternal angle, and the catheter length determined by adding the insertion depth to the tunnel length.

With the patient in supine position in their ICU bed, the right side of the neck and chest was prepared using chlorhexidine prep and sterile drapes. The right IJ vein was identified using a sterile ultrasound probe and 2% lidocaine was injected at the puncture site. Using a micro-puncture set (21G needle, 4F coaxial sheath and 0.018” wire), the right IJ vein was punctured under ultrasound guidance with subsequent advancement of a 0.018” wire. The coaxial sheath was withdrawn and the 0.018” wire was replaced with 0.035” wire under continuous cardiac monitoring to evaluate for cardiac ectopy, providing indirect evidence of the location of the wire tip in the right atrium. Lidocaine was infiltrated at the chosen exit site and a small skin incision was made with the tunneled catheter advanced into the tunnel.
Using Seldinger’s technique, the venotomy was serially dilated and a peel-away sheath was advanced and the wire withdrawn. The catheter was advanced by gradually peeling off the sheath. The threshold to abandon the procedure was low if there was any difficulty advancing the wire or the dilators. All catheter ports were checked for adequate flow with a 10 ml syringe, flushed and locked with 4% citrate solution and sterile dressing was applied. The catheter tip position was confirmed with a post-procedure portable chest radiograph.

**DATA ACQUISITION AND STATISTICAL ANALYSES**

The Cleveland Clinic has utilized an electronic health record (EHR) for inpatient and outpatient care since 2001. Data gathered from the EHR included age at the time of TDC insertion, sex, race/ethnicity, comorbidities, body mass index, reason for ICU admission, indication for TDC placement, use of anti-platelet/anti-coagulant medications, the Acute Physiology and Chronic Health Evaluation (APACHE II) score, catheter placement related complications and components of dialysis prescription.

Race/ethnicity was identified based on self-description as recorded in the EHR, and was categorized as Caucasian, African-American, Hispanic, Asian, or other (categorized as other when they were not classified as any of the aforementioned ethnicities or when race data were not available). Comorbid conditions included hypertension, diabetes mellitus, dyslipidemia, malignancy, coronary artery disease, cerebrovascular disease, end-stage liver disease, chronic kidney disease and congestive heart failure.

Catheter placement related complications included bleeding, inadvertent arterial puncture, venous air embolism, arrhythmias, pneumothorax, hemothorax and catheter malposition [9,10]. Procedure related clinically significant bleeding was defined as any bleeding requiring blood transfusions or any additional and unexpected hemostatic measures [15]. The desired position for the catheter tip was considered to be in the mid-right atrium or at the junction of the SVC and the right atrium and catheter malposition was defined as either incorrect initial positioning of the catheter tip, displacement of the catheter tip after placement, or folding/kinking of the catheter tip [11]. The complications observed in this study were classified according to the reporting standards of the American Society of Diagnostic and Interventional Nephrology (ASDIN) [16].

The TDC placement procedure was classified as successful if the catheter was able to achieve blood flow and circuit venous pressures sufficient to perform a single intermittent hemodialysis treatment or a 24-hour treatment with continuous kidney replacement therapy without significantly changing the dialysis prescription. The components of the dialysis prescription included the choice of hemodialysis membrane, dialysis session length, dialysate composition and temperature, blood flow rate, amount and rate of ultrafiltration, and method of anticoagulation.

Descriptive statistics of patient characteristics were presented in median and interquartile range for continuous variables, and in frequencies and percentages for categorical variables.

**Results**
BASELINE PATIENT CHARACTERISTICS

A total of 25 patients infected with COVID-19 who underwent right IJ TDC placement at the bedside in the ICU between April 1st -December 31st 2020, utilizing only anatomic landmarks and ultrasound for real-time guidance without fluoroscopy, were included in the analysis. 21 patients had clinically apparent COVID-19 pneumonia at the time of TDC placement, requiring varying degrees of respiratory support (mechanical ventilation [MV] [n = 11]; non-invasive ventilation [NIV] [n = 5]; high-flow nasal oxygen [HFNO] [n = 2] and nasal cannula [n = 3]); 4 COVID-19 infected patients did not exhibit any acute respiratory illness and were admitted to the ICU for other indications including management of gastrointestinal bleeding (n = 2) and hepatorenal syndrome (n = 2). Tunneled central venous catheters (small bore [5 Fr]; single or double lumen) for infusion were concomitantly inserted into the right IJ vein in 10 of these patients. The patients in our cohort (Table 2) had a median age of 62 years (interquartile range [IQR]: 55–70), including 18 men (72%) and 16 African Americans (64%), with a median body mass index of 28.8 (IQR: 25.2–33.2) kg/m² and median APACHE II score of 22 (IQR: 19–25).

Baseline kidney function was available for all our patients, 11 of whom did not have a history of chronic kidney disease with a baseline estimated glomerular filtration rate (eGFR) of greater than or equal to 60 mL/min/1.73 m². 8 and 5 patients had chronic kidney disease stages 3 (eGFR of 30–59 mL/min/1.73 m²) and 4 (eGFR of 15–29 mL/min/1.73 m²) respectively. Only one of our patients had been on hemodialysis prior to hospitalization via a right upper extremity arteriovenous fistula and required TDC insertion for initiation of continuous renal replacement therapy (CRRT). Other comorbid conditions included diabetes mellitus (n = 12), hypertension (n = 18), congestive heart failure (n = 7) and end-stage liver disease (n = 2).

CATHETER FUNCTION FOLLOWING BEDSIDE TDC PLACEMENT

Patients in our series had their initial non-tunneled hemodialysis access replaced through a fresh venipuncture with a TDC at bedside a median of 6 days (IQR: 4–7) after initiation of hemodialysis. Continuous veno-venous hemodialysis (CVVHD) was the CRRT modality employed in all patients. Median catheter blood flow, dialysate flow and ultrafiltration rates of 200 (IQR: 200–200) ml/min, 2000 (IQR: 1800–2300) ml/hour and 100 (IQR: 100–200) ml/hour were achieved respectively without any deviations from the dialysis prescription (Table 3).

SAFETY OUTCOMES FOLLOWING BEDSIDE TDC PLACEMENT

No catheter placement related complications including bleeding, arterial puncture, venous air embolism, arrhythmias, pneumothorax or hemothorax were observed in our patients for the duration of their hospitalization. None of the catheter tips were mal-positioned on post-insertion chest radiographs, with
the tip located either in the mid-right atrium (n = 22) or at the junction of the SVC and the right atrium (n = 3) (Table 3).

Discussion

Medical ICU practitioners and hospital administrators may prepare for a potential surge in critical care capacity during the global COVID-19 pandemic by optimizing workflows for rapid diagnosis, isolation, clinical management as well as addressing concerns relating to supplies and infrastructure [17]. However, these preparations must also focus on the ICU staff, including protection from nosocomial transmission [18]. This is particularly crucial with hypoxic COVID-19 patients requiring non-invasive respiratory support, including NIV and HFNO, since these may generate aerosols composed of small virus-containing particles, depending on factors such as duration of use, oxygen flow velocity, mask leakage as well as patient coughing and cooperation [19]. Our study was conceptually innovative in attempting to explore bedside TDC insertion as a viable alternative in order to help prevent hospital-acquired infections without compromising patient safety or quality of care. We describe a series of 25 patients infected with COVID-19 requiring kidney replacement therapy that underwent bedside placement of right IJ TDCs in the ICU, using only ultrasound and anatomic landmarks without fluoroscopic guidance.

The standard of care for TDC insertion dictates that the procedure be performed under ultrasound and fluoroscopic guidance to ensure fewer catheter placement related complications and adequate catheter function [6]. Complications arising from TDC insertion including catheter related infections and thrombosis contribute significantly to patients’ morbidity and mortality at a considerable economic burden on society [8, 20]. The hypercoagulable state of patients with COVID-19 also makes them potentially more vulnerable to thrombotic complications and catheter occlusion [21, 22]. Furthermore, it is important to ensure that the patients are comfortable whilst they are placed in the supine position in order to improve cooperation during the procedure and reduce the risk of insertion failure or catheter mal-positioning [23]. However, it may be challenging to provide a balanced analgesic strategy during TDC placement to provide adequate discomfort relief whilst ensuring respiratory and cardiovascular stability, especially in patients on respiratory support requiring conscious sedation. Therefore, we implemented certain precautionary measures into our protocol for bedside TDC placement in patients with COVID-19 to mitigate the risk of developing catheter related complications.

Firstly, we developed rigorous selection criteria for patients with COVID-19 under consideration for TDC insertion in an attempt to identify ideal candidates. In addition to excluding patients with absolute contraindications to TDC insertion including sepsis/bacteremia and uncontrolled coagulopathies [6], we also did not attempt bedside TDC placement in patients with new onset cardio-respiratory instability or with a history of central vein stenotic/occlusive disease.

Secondly, we selected the right IJ vein as the preferred site for bedside TDC placement to further try to minimize the risk of catheter dysfunction and placement related complications. Blood flow rates are consistently higher with right-sided jugular venous catheters than with left sided catheters since
placement of catheters into the left IJ vein requires that the catheter make two right angled bends as well as an antero-posterior bend over the pulmonary arch prior to reaching the SVC [24]. There is additional resistance to flow not only from the multiple bends but also from the longer length of the catheter on the left-side. A retrospective analysis of jugular venous catheters depicted that left-sided IJ venous catheters had higher rates of infection (0.50 vs 0.27; \( P = .005 \)) and catheter dysfunction (0.25 vs 0.11; \( P = .036 \)) compared with those inserted from the right [25]. Therefore, the longer path that a left sided catheter has to traverse, predisposes it to developing catheter dysfunction as opposed to a right sided catheter, which has a relatively shorter, less meandering course to the SVC.

Utilizing our protocol and implementing the aforementioned safety measures, we were successfully able to place TDCs at the bedside in patients with COVID-19 requiring kidney replacement therapy and achieved adequate catheter blood flow rates without any deviation from the CVVHD prescription or evidence of catheter occlusion/dysfunction. Furthermore, no catheter placement related complications were observed and none of the catheter tips were mal-positioned on post-insertion chest radiographs. The acute escalation in the proportion of critically ill COVID-19 patients with acute kidney injury and the overwhelming need for urgent kidney replacement resources, coupled with the prospect of having to transport all these patients outside the ICU to the fluoroscopy suite for TDC placement mandated the consideration of bedside TDC insertion. In addition to protecting hospital personnel from COVID-19 exposure by limiting transportation needs, we further limited potential nosocomial transmission amongst health care workers by eliminating the involvement of multiple teams for the procedure.

Moreover, we were able to concomitantly place tunneled central venous catheters (small bore [5 Fr]; single or double lumen) along with TDCs in the right IJ vein in 10 of our patients, potentially further reducing personnel exposure to COVID-19. The prospect of concomitant placement of multiple catheters in a single central vein may ignite concerns regarding increased risk of catheter-related complications including infections and thrombosis as well as puncture related complications such as pneumothorax. Furthermore, with concomitant placement of a small-bore central venous catheter with a central hemodialysis catheter, there may even be concerns regarding hemodialysis catheter dysfunction. However, one retrospective analysis [26] compared patients who had undergone concomitant placement of a hemodialysis catheter and a central venous catheter for infusion with patients who only had a hemodialysis catheter placed in their right IJ vein. No significant differences were found between the aforementioned two groups of patients in the incidence of thrombosis (1.0 % vs 0.0%, \( p > 0.999 \)), line infection (2.1% vs 0.0%, \( p = 0.519 \)), or line dysfunction (2.1% vs 0.0%, \( p = 0.516 \)). No puncture related complications such as pneumothorax were reported for either group. Therefore, even though multiple catheters are not routinely placed in the same central vein, the simultaneous placement of multiple catheters may be considered if necessary, without increasing the risk of complications.

It is encouraging to note that another case series at a tertiary community-based medical center has also reported successful placement of 24 bedside TDCs by the institution's vascular surgery department [27]. Only one patient out of the series developed a catheter placement related complication, which was pneumothorax and cardiac tamponade. Some important distinctions between our studies include: (a)
some of their TDC insertions utilized fluoroscopic guidance requiring movement of the patient to a fluoroscopy compatible bed whereas only ultrasound was used in all our procedures for real-time guidance (b) chest radiography was utilized at the time of sheath insertion in their series with a median of 5 plain radiographs taken during TDC insertion, whilst only one post-procedure chest radiograph was performed in our patients for confirmation of catheter tip position (c) we have clearly stated the selection criteria for patient candidacy for bedside TDC insertion to identify ideal candidates in an attempt to mitigate the risk of catheter related complications (d) concomitant placement of TDCs and tunneled central venous catheters in the right IJ vein was performed in our series.

Conclusions

In conclusion, preferential right IJ TDC placement at bedside in a carefully selected group of patients with COVID-19, using ultrasound and anatomic landmarks without fluoroscopic guidance, may potentially reduce the risk of transmission of COVID-19 amongst health care workers without compromising patient safety or catheter function. Concomitant insertion of tunneled central venous catheters in the right IJ vein may also be safely accomplished and further help limit personnel exposure to COVID-19.

Lessons learned from our experience are valuable to improving the safety of TDC placement in regions where access to fluoroscopy may be limited. The standard teaching of utilizing both ultrasound and fluoroscopy guidance for TDC placement creates an impediment to providing timely care and dependence on other specialties [28]. Our experience with a carefully selected population may translate to several other clinical scenarios − 1) limited access to fluoroscopy in resource limited countries; 2) regional and local regulatory restrictions on fluoroscopy use by physicians other than radiologists; 3) preventing transmission of infections including clostridium difficile, vancomycin resistant enterococci and other multi-drug resistant organisms; 4) patient related limitations precluding the use of fluoroscopy (e.g. pregnancy); 5) challenges with transporting patients with difficult body habitus (e.g. morbid obesity).

Abbreviations

1. Coronavirus disease-2019 (COVID-19)
2. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
3. Intensive care unit (ICU)
4. Tunneled hemodialysis catheter (TDC)
5. Superior vena cava (SVC)
6. Internal jugular (IJ)
7. Personal protective equipment (PPE)
8. Electronic health record (EHR)
9. Acute Physiology and Chronic Health Evaluation (APACHE II)
10. American Society of Diagnostic and Interventional Nephrology (ASDIN)
11. Mechanical ventilation [MV]
12. Non-invasive ventilation [NIV]
13. High-flow nasal oxygen [HFNO]
14. Interquartile range [IQR]
15. Estimated glomerular filtration rate (eGFR)
16. Continuous renal replacement therapy (CRRT)
17. Continuous veno-venous hemodialysis (CVVHD)

Declarations

ETHICS APPROVAL AND CONSENT TO PARTICIPATE

The study protocol was reviewed and approved by the institutional review board at the Cleveland Clinic (Reference Number 20-1206) and the protocol was exempted from the requirement for informed consent from patients since only de-identified data collected during hospital visits were included in the study.

CONSENT FOR PUBLICATION

Not applicable.

AVAILABILITY OF DATA AND MATERIALS

All data generated or analyzed during this study are included in this published article.

COMPETING INTERESTS

The authors declare that they have no competing interests.

FUNDING

No funding to declare.

AUTHOR'S CONTRIBUTIONS

The authors confirm contribution to the paper as follows: MAS, TJV, TH and JL contributed to the study’s conception and design, MAS and JL carried out data collection, MAS, TJV, TH and JL contributed to the data analysis and interpretation of results as well as draft manuscript preparation. All authors reviewed the results and approved the final version of the manuscript.

Mohammad A. Sohail MD: (MAS)
Tushar J. Vachharajani MD, FASN: (TJV)
Tarik Hanane MD: (TH)
James Lane RN, BSN: (JL)

ACKNOWLEDGEMENTS

Preliminary data published in Abstract:

M.A. SOHAIL, J. Lane, T. Hanane, T. Vachharajani, POS-211 SAFETY AND EFFICACY OF BEDSIDE PLACEMENT OF TUNNELED HEMODIALYSIS CATHETERS IN PATIENTS WITH COVID-19 IN THE INTENSIVE CARE UNIT, Kidney International Reports, Volume 6, Issue 4, Supplement, 2021, Pages S88-S89, ISSN 2468-0249, https://doi.org/10.1016/j.ekir.2021.03.224.

References

1. Islam MS, Rahman KM, Sun Y, Qureshi MO, Abdi I, Chughtai AA, et al. Current knowledge of COVID-19 and infection prevention and control strategies in healthcare settings: A global analysis. Infect Control Hosp Epidemiol. 2020;41(10):1196–206.

2. Phua J, Weng L, Ling L, Egi M, Lim C-M, Divatia JV, et al. Intensive care management of coronavirus disease 2019 (COVID-19): challenges and recommendations. Lancet Respir Med. 2020;8(5):506–17.

3. Naicker S, Yang C-W, Hwang S-J, Liu B-C, Chen J-H, Jha V. The Novel Coronavirus 2019 epidemic and kidneys. Kidney Int. 2020;97(5):824–8.

4. Hirsch JS, Ng JH, Ross DW, Sharma P, Shah HH, Barnett RL, et al. Acute kidney injury in patients hospitalized with COVID-19. Kidney Int. 2020;98(1):209–18.

5. Fisher M, Neugarten J, Bellin E, Yunes M, Stahl L, Johns TS, et al. AKI in hospitalized patients with and without COVID-19: A comparison study. J Am Soc Nephrol. 2020;31(9):2145–57.

6. Lok CE, Huber TS, Lee T, Shenoy S, Yevzlin AS, Abreo K, et al. KDOQI Clinical Practice Guideline for Vascular Access: 2019 update. Am J Kidney Dis. 2020;75(4 Suppl 2):S1–164.

7. Motta Elias R, da Silva Makida SC, Abensur H, Martins Castro MC, Affonso Moysés RM, Pereira BJ, et al. Insertion of tunneled hemodialysis catheters without fluoroscopy. J Vasc Access. 2010;11(2):138–42.

8. Hodzic S, Golic D, Smajic J, Sijercic S, Umihanic S, Umihanic S. Complications related to insertion and use of central Venous Catheters (CVC). Med Arch. 2014;68(5):300–3.

9. McGee DC, Gould MK. Preventing complications of central venous catheterization. N Engl J Med. 2003;348(12):1123–33.

10. Eisen LA, Narasimhan M, Berger JS, Mayo PH, Rosen MJ, Schneider RF. Mechanical complications of central venous catheters. J Intensive Care Med. 2006;21(1):40–6.

11. Vesely TM. Central venous catheter tip position: a continuing controversy. J Vasc Interv Radiol. 2003;14(5):527–34.

12. Loveday HP, Wilson JA, Pratt RJ, Golsorkhi M, Tingle A, Bak A, et al. epic3: national evidence-based guidelines for preventing healthcare-associated infections in NHS hospitals in England. J Hosp
13. Miller DL, O'Grady NP, Society of Interventional Radiology. Guidelines for the prevention of intravascular catheter-related infections: recommendations relevant to interventional radiology for venous catheter placement and maintenance. J Vasc Interv Radiol. 2012;23(8):997–1007.

14. Stonelake PA, Bodenham AR. The carina as a radiological landmark for central venous catheter tip position. Br J Anaesth. 2006;96(3):335–40.

15. Giannini EG, Greco A, Marenco S, Andorno E, Valente U, Savarino V. Incidence of bleeding following invasive procedures in patients with thrombocytopenia and advanced liver disease. Clin Gastroenterol Hepatol. 2010;8(10):899–902; quiz e109.

16. Vesely TM, Beathard G, Ash S, Hoggard J, Schon D, ASDIN Clinical Practice Committee. Classification of complications associated with hemodialysis vascular access procedures. A position statement from the American Society of Diagnostic and Interventional Nephrology. J Vasc Access. 2008;9(1):12–9.

17. Vergano M, Bertolini G, Giannini A, Gristina GR, Livigni S, Mistraletti G, et al. Clinical ethics recommendations for the allocation of intensive care treatments in exceptional, resource-limited circumstances: the Italian perspective during the COVID-19 epidemic. Crit Care. 2020;24(1):165.

18. Adams JG, Walls RM. Supporting the health care workforce during the COVID-19 global epidemic. JAMA. 2020;323(15):1439–40.

19. Guan L, Zhou L, Zhang J, Peng W, Chen R. More awareness is needed for severe acute respiratory syndrome coronavirus 2019 transmission through exhaled air during non-invasive respiratory support: experience from China. Eur Respir J. 2020;55(3):2000352.

20. Ziegler MJ, Pellegrini DC, Safdar N. Attributable mortality of central line associated bloodstream infection: systematic review and meta-analysis. Infection. 2015;43(1):29–36.

21. Helms J, Tacquard C, Severac F, Leonard-Lorant I, Ohana M, Delabranche X, et al. High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study. Intensive Care Med. 2020;46(6):1089–98.

22. Panigada M, Bottino N, Tagliabue P, Grasselli G, Novembrino C, Chantarangkul V, et al. Hypercoagulability of COVID-19 patients in intensive care unit: A report of thromboelastography findings and other parameters of hemostasis. J Thromb Haemost. 2020;18(7):1738–42.

23. Donati A, Damiani E, Adrario E, Romano R, Pelaia P. Pain and discomfort management during central venous catheter insertion. Indian J Crit Care Med. 2014;18(7):417–8.

24. Oliver MJ, Edwards LJ, Treleaven DJ, Lambert K, Margetts PJ. Randomized study of temporary hemodialysis catheters. Int J Artif Organs. 2002;25(1):40–4.

25. Engstrom BI, Horvath JJ, Stewart JK, Sydnor RH, Miller MJ, Smith TP, et al. Tunneled internal jugular hemodialysis catheters: impact of laterality and tip position on catheter dysfunction and infection rates. J Vasc Interv Radiol. 2013;24(9):1295–302.

26. Spitzer B, Kirkland K, Reyes J, Helmer SD, Ammar C, Subbarao C. Concomitant placement of dialysis and infusion catheters in the right internal jugular vein in the intensive care setting: Is it safe? J Vasc
27. Williams AD, Qaqish M, Elnagar J, Michos L, Nantermet S, Meisner R, et al. Bedside tunneled hemodialysis catheter placement in patients with COVID-19. Ann Vasc Surg. 2021;73:133–8.

28. Vachharajani TJ, Kim Y-S, Riella M, Harris D, Jha V, International Society of Nephrology Interventional Nephrology Working Group. International Society of Nephrology’s initiative on interventional nephrology minimum training and program-building standards in resource-limited countries. Kidney Int. 2020;98(5):1067–70.

**Tables**

**Table 1: Pre-procedural Inclusion and Exclusion Criteria prior to TDC Insertion**

TDC: Tunneled Hemodialysis Catheter; INR: International Normalized Ratio; TEG: Thrombo-elastography

1. Kang YG, Martin DJ, Marquez J, Lewis JH, Bontempo FA, Shaw BW Jr, et al. Intraoperative changes in blood coagulation and thrombelastographic monitoring in liver transplantation. Anesth Analg. 1985;64(9):888–96.

| Inclusion Criteria: |
|---------------------|
| 1. Confirmation of patency of the right internal jugular vein via bedside ultrasound assessment |
| 2. Appropriate withdrawal of anticoagulation (heparin and direct oral anticoagulants stopped 4 and 72 hours prior to the procedure respectively) |
| 3. Arrangement of nothing by mouth status 4 hours prior to procedure |
| 4. Appropriate blood product transfusions to keep platelet count greater than 20,000 k/uL, INR less than 2 and normalize TEG parameters in patients with liver disease (reaction time less than 15 min, α-angle greater than 45 degrees and maximum amplitude greater than 30 mm) to minimize risk of procedure-related bleeding complications [1] |

| Exclusion Criteria: |
|---------------------|
| 1. History of thoracic central vein occlusive/stenotic disease |
| 2. History of superior vena cava stent placement or recanalization |
| 3. Hemodynamic instability defined as either a new requirement for vasoactive support or new-onset cardiac dysrhythmia within 4 hours of scheduled TDC placement or increase in existing vasoactive support of greater than 15 mcg of norepinephrine or greater than 150 mcg of phenylephrine within 2 hours of planned TDC insertion |
| 4. Respiratory instability defined as an inability to maintain an oxygen saturation of greater than 90% in the supine position, significant risk of aspiration in the supine position or a recent increase in oxygen requirements defined as an increment in FiO2 of greater than 20% within 4 hours of scheduled TDC placement |
| 5. Blood cultures negative for less than 48 hours prior to planned TDC insertion |
Table 2: Baseline Clinical Characteristics

eGFR: Estimated Glomerular Filtration Rate; IQR: Interquartile Range; APACHE II: Acute Physiology and Chronic Health Evaluation II
|                                | All Patients (N = 25)       |
|--------------------------------|-----------------------------|
| Age, median (IQR)              | 62.0 (55.0-70.0)            |
| Male, n (%)                    | 18 (72)                     |
| African American, n (%)        | 16 (64)                     |
| Status of COVID-19 Infection, n (%) |                      |
| No Acute Respiratory Illness   | 4 (16)                      |
| Clinically Apparent COVID-19 Pneumonia | 21 (84)                  |
| Comorbidities, n (%)           |                             |
| Hypertension                   | 18 (72)                     |
| Diabetes Mellitus              | 12 (48)                     |
| Chronic Kidney Disease         | 14 (56)                     |
| Congestive Heart Failure       | 7 (28)                      |
| End-Stage Liver Disease        | 2 (8)                       |
| Body mass index, kg/m², median (IQR) | 28.8 (25.2-33.2)          |
| Baseline eGFR (mL/min/1.73m²)  |                             |
| >60                            | 11 (44)                     |
| 30-59                          | 8 (32)                      |
| 15-29                          | 5 (20)                      |
| <15                            | 1 (4)                       |
| APACHE II Score, median (IQR)  | 22.0 (19.0-25.0)            |

**Table 3: CVVHD Prescription and Tunneled Dialysis Catheter Outcomes**

CVVHD: Continuous Veno-Venous Hemodialysis; IQR: Interquartile Range
## All Patients (N = 25)

| CVVHD Prescription, median (IQR)                |          |
|------------------------------------------------|----------|
| Dialysate Flow Rate, mL/hour                   | 2000 (1800-2300) |
| Blood Flow Rate, mL/minute                     | 200 (200-200)  |
| Ultrafiltration Rate, mL/hour                   | 100 (100-200)  |

| Tunneled Dialysis Catheter Tip Positioning, n (%) |          |
|--------------------------------------------------|----------|
| Mid – Right Atrium                               | 22 (88)  |
| Superior Vena Cava – Right Atrium Junction       | 3 (12)   |
| Catheter Malposition                            | 0 (0)    |

| Tunneled Dialysis Catheter Safety Outcomes, n (%) |          |
|--------------------------------------------------|----------|
| Bleeding/ Arterial puncture                       | 0 (0)    |
| Venous Air Embolism                               | 0 (0)    |
| Arrhythmias                                       | 0 (0)    |
| Pneumothorax/Hemothorax                           | 0 (0)    |

### Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [GraphicalAbstractCriticalCareCOVIDTDC07292021.png](GraphicalAbstractCriticalCareCOVIDTDC07292021.png)